Avanos Medical, Inc.
NYSE:AVNSMedical - Devices
+$0.06 today
- Market cap
- $1.17B
- Beta
- 1.57
- P/E (TTM)
- -16.7
- EPS (TTM)
- -$1.50
Volume 0.43M
Average 1.49M
AVNS Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Avanos Medical, Inc.NYSE: AVNS
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables dips below year-ago levels
Q1 FY2026 accounts payables of $2.1M (cash outflow) fell 67.2% year over year, behind the +151.0% change in trailing-twelve-month accounts payables. Over 3 fiscal years it compounded at -74.3% a year.
Context
- Accounts payables amounted to 0.1% of revenue in FY2025, unchanged from a year earlier.
- Accounts payables increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -67.2% toward the trailing-twelve-month pace of +151.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 600K USD
- Year-over-year change
- +166.7%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 600K | +166.7% |
| FY2024 | 2024-12-31 | (900K) | +93.8% |
| FY2023 | 2023-12-31 | (14.4M) | -140.7% |
| FY2022 | 2022-12-31 | 35.4M | +397.5% |
| FY2021 | 2021-12-31 | (11.9M) | — |
Accounts Payables vs competitors
How AVNS compares with its peers on the latest reported figures
- AVNS's LTM Mar 2026 accounts payables of $4.9M is the 6th largest of the 11 companies compared; the peer median is $56.5K.
- Its year-over-year change of +151.0% is the 4th highest of 11, against a peer median of -65.9%.
- Accounts payables amounts to 0.7% of revenue for AVNS, versus a peer median of 1.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $267M | -205.5% | -38.9% | 1.2% | |
| LTM Apr 2026 | $22.9M | +1661.5% | -32.0% | 2.7% | |
| LTM Mar 2026 | $10.54M | +15832.8% | — | 11.9% | |
| LTM Mar 2026 | $8.06M | -62.2% | — | 1.4% | |
| LTM Mar 2026 | $5.77M | +897.9% | — | 14.2% | |
| LTM Mar 2026 | $4.9M | +151.0% | -74.3% | 0.7% | |
| LTM Mar 2026 | $1.2M | -69.6% | — | 1.9% | |
| LTM Mar 2026 | $571K | -82.0% | — | 0.7% | |
CBLLCeriBell, Inc. | LTM Mar 2026 | $543K | +86.6% | +141.4% | 0.6% |
| LTM Mar 2026 | $428K | -82.0% | -37.8% | 0.2% | |
| LTM Mar 2026 | $315K | -95.3% | +34.3% | 0.2% | |
| Peer median (excluding AVNS) | $56.5K | -65.9% | -32.0% | 1.3% | |
Competitors are the stored peer set for AVNS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 5.2M | 50.5M | (61.8M) | (392.1M) | (72.9M) |
| Depreciation & Amortization | 38.3M | 47.7M | 46.1M | 45.5M | 38.9M |
| Deferred Income Tax | (3.4M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 13.2M | 15.9M | 15.8M | 13.8M | 12.6M |
| Change in Working Capital | 26M | (24.3M) | (18M) | 35M | 9.8M |
| Accounts Receivables | (10.8M) | (24.7M) | 39M | (6.6M) | 30.9M |
| Inventory | 17.2M | (30.9M) | 4.7M | 39M | 200K |
| Accounts Payables | (11.9M) | 35.4M | (14.4M) | (900K) | 600K |
| Other Working Capital | 31.5M | (4.1M) | (47.3M) | 3.5M | (21.9M) |
| Other Non-Cash Items | 8M | 1.1M | 50.3M | 398.5M | 86.3M |
| Operating Cash Flow | 87.3M | 90.9M | 32.4M | 100.7M | 74.7M |
| Capital Expenditures | (21M) | (19.3M) | (17.8M) | (17.8M) | (31.6M) |
| Acquisitions (Net) | 0 | (116.1M) | 39.4M | (9.7M) | (28M) |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | (1M) |
| Investing Cash Flow | (21M) | (135.4M) | 21.6M | (27.5M) | (60.6M) |
| Debt Repayment | (50M) | 103.4M | (64.7M) | (33.6M) | (34.4M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 700K |
| Common Stock Repurchased | (11.5M) | (45.5M) | (19.1M) | (12.8M) | (3.3M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 6.2M | (1.2M) | (10.4M) | (2.7M) | 0 |
| Financing Cash Flow | (55.3M) | 56.7M | (94.2M) | (49.1M) | (37M) |
| Effect of Forex Changes | (4M) | (3M) | 200K | (4.1M) | 5M |
| Net Change in Cash | 7M | 9.2M | (40M) | 20M | (17.9M) |
| Free Cash Flow | 66.3M | 71.6M | 14.6M | 82.9M | 43.1M |
Avanos Medical, Inc.
NYSE:AVNS
Intrinsic Alpha fair value
Locked
Current Price
$24.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.